Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in a fireside chat at the Stifel Healthcare Conference on November 16, 2022, at 4:10 p.m. ET. The live webcast will be accessible under the Investors tab on Acumen's website, where it will be archived for 14 days.
Acumen focuses on developing novel therapeutics for Alzheimer’s disease, targeting toxic soluble AβOs with its investigational product candidate, ACU193, currently in a Phase 1 clinical trial for early Alzheimer’s patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q3 2022 financial results on November 14, 2022, followed by a conference call at 4:30 p.m. ET. This call aims to provide a comprehensive business and financial update regarding the company's operations. Acumen is focused on developing innovative therapeutics for Alzheimer's disease, specifically targeting soluble AβOs with its candidate ACU193 in a Phase 1 clinical trial.
Acumen Pharmaceuticals announced the publication of its clinical development plan for ACU193, a monoclonal antibody targeting toxic soluble amyloid beta oligomers, in the Journal of Prevention of Alzheimer’s Disease. The ongoing Phase 1 clinical trial, INTERCEPT-AD, aims to evaluate the safety and efficacy of ACU193 in early Alzheimer’s disease patients. The FDA has granted Fast Track designation for this therapy, which may accelerate its path to market. Future trial phases will be guided by safety, pharmacokinetics, and cognitive measures for potential registration.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced that its investigational drug, ACU193, has received Fast Track designation from the FDA for treating early Alzheimer’s disease. ACU193 targets toxic soluble amyloid beta oligomers, which are believed to contribute to neurodegeneration. Currently in the Phase 1 INTERCEPT-AD trial, the drug aims to establish safety and proof of mechanism with 62 participants. The Fast Track status facilitates closer collaboration with the FDA, enhancing the potential for expedited review and approval.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported financial results for Q2 2022, revealing a cash balance of $209.9 million as of June 30, anticipated to fund operations until 2025. The ongoing INTERCEPT-AD Phase 1 trial for ACU193 aims to deliver topline results in H1 2023, with 15 active clinical sites currently enrolling patients. R&D expenses surged to $7.3 million, reflecting increased clinical trial costs. Net loss decreased to $10.2 million compared to $61.4 million a year prior, influenced by significant prior year non-cash expenses.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will announce its Q2 2022 financial results on August 15, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on novel therapies for Alzheimer’s disease and is advancing its investigational drug, ACU193, in a Phase I clinical trial. Acumen has established itself in the biopharmaceutical sector, targeting the toxic Aβ oligomers linked to Alzheimer’s pathology. The audio from the call will be accessible via their website, with an archived version available for 30 days.
Acumen Pharmaceuticals has developed a synthetic model for soluble amyloid beta oligomers (AβOs), crucial for Alzheimer’s disease research. This model aims to standardize assays for AβOs, which have been challenging to study due to their complexity. The methodology will be presented at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. The ongoing Phase 1 clinical trial of ACU193, targeting toxic AβOs, is expected to yield important data to advance Alzheimer’s research.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced its participation in two upcoming major conferences focusing on Alzheimer's disease. At the Alzheimer’s Association International Conference (AAIC) in San Diego, the company will present a poster on August 3, 2022, detailing their research on amyloid beta oligomers. Additionally, Dr. Eric Siemers, Chief Medical Officer, will speak at the BTIG Biotech Conference on August 8, 2022, discussing next-generation therapeutics targeting Alzheimer's pathology. Acumen is advancing its investigational product ACU193, a monoclonal antibody in Phase 1 trials.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2022 financial results, highlighting a cash balance of $216.7 million as of March 31, 2022, sufficient to fund operations through 2025. The company is advancing its Phase 1 clinical trial, INTERCEPT-AD, for its drug ACU193 targeting early Alzheimer’s disease, with topline data expected in the first half of 2023. R&D expenses increased to $6.0 million from $2.6 million YoY, reflecting ongoing trial costs. Acumen's net loss for the quarter was $9.1 million, a decrease from $27.0 million in Q1 2021.
Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q1 2022 financial results on May 16, 2022, at 4:30 PM ET. The company will host a conference call and a live audio webcast to discuss business performance and financial updates. Acumen is focused on developing a novel therapy for Alzheimer’s disease, specifically targeting toxic AβOs through its investigational drug, ACU193, currently in Phase I trials. Interested investors can access the live webcast via the company’s website.